Insulet Corporation (PODD) Receives Analyst Rating

Insulet Corporation (PODD) : 8 brokerage houses believe that Insulet Corporation (PODD) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Insulet Corporation (PODD). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 14 Wall Street Analysts endorse the stock as a Buy with a rating of 1.79.

Insulet Corporation (PODD) : The consensus price target for Insulet Corporation (PODD) is $43.48 for the short term with a standard deviation of $4.78. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $52, however, the pessimist price target for the company is $39.


Also, Brokerage firm Jefferies maintains its rating on Insulet Corporation (NASDAQ:PODD). As per the latest information, the brokerage house raises the price target to $45 per share from a prior target of $41. The shares have been rated Buy. The rating by the firm was issued on August 4, 2016.

Insulet Corporation (NASDAQ:PODD): After opening at $41.24, the stock dipped to an intraday low of $40.73 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $42.25 and the buying power remained strong till the end. The stock closed at $42.17 for the day, a gain of 2.26% for the day session. The total traded volume was 452,989. The stocks close on the previous trading day was $41.24.

Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.